Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A

Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A — Trials · CancerIndex

Clinical trials

Registered studies

15 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01139970	Veliparib and Temozolomide in Treating Patients With Acute Leukemia	completed	Phase 1	66	National Cancer Institute (NCI)NIH	1	Nov 20, 2025	clinicaltrials
NCT00588991	Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders	completed	Phase 1	12	National Cancer Institute (NCI)NIH	1	Apr 2, 2025